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Introduction:
Our proposal exploits a new technology, MagSweeper, for isolation of Circulating Tumor Cells from patients with prostate cancer. MagSweeper is an automated immunomagnetic separation technology that gently extracts CTCs from whole blood, allowing the possibility of characterization of the cells molecularly. The MagSweeper isolates completely purified CTCs while preserving the integrity and viability of these fragile cells and eliminating contamination from nonspecific adsorption or entrapment of other blood cells. We proposed 3 specific aims in this project. We are excited to submit the project closing report in which we have made significant progress on all proposed aims. Our research has also resulted in a high quality research publication which is attached at the end of the report.
Specific Aim 1: To optimize MagSweeper technology for purification of prostate CTCs:
Our first objective was to utilize our optimized MagSweeper protocol for isolation of circulating tumor cells from prostate cancer patients. However, in a continued effort to improve the performance of MagSweeper, we continued cell spiking experiments (n=54 experiments and 11 blood samples). In these experiments, we spiked 100 LNCaP cells into 3.75 ml of whole blood and isolated the cells using MagSweeper. The experimental conditions were: prior to spiking, LNCaP cell viability was measured by Trypan blue exclusion which was found to be 89%±8%. In addition, LNCaP cells were fluorescently labeled with antibodies against EpCAM and CD45 to distinguish LNCaPs from WBCs. DAPI stain was used to identify dead (membrane compromised) cells. Post-isolation we recovered a mean of 81%±16% of live spiked LNCaP cells (EpCAM+/CD45-/DAPI-) ( Figure 1B ) while DAPI staining revealed an additional 12%±6% of the isolated LNCaP cells that were membrane compromised as occurs in dead cells (EpCAM+/CD45-/DAPI+). Since the original cell spike contained 11% dead cells (measured by Trypan blue exclusion) recovery of 12% DAPI positive cells following MagSweeping indicates that damage to spiked LNCaP cells during the entire procedure is minimal. Normal, unspiked blood samples failed to yield EpCAM positive cells (data not shown).
KEY RESEARCH ACCOMPLISHMENTS:
• MagSweeper and the optimized protocol can consistently isolate EpCAM expressing LNCaP with maximum efficiency and purity and with minimal cell death.
Specific Aim 2: To test whether MagSweeper can successfully isolate CTCs from patients with localized and metastatic prostate cancer
We have tested this same CTC isolation protocol on isolating circulating tumor cells from metastatic prostate cancer patients. So far we have recruited 82 patients with metastatic castrate resistant prostate cancer (CRPC) and found live CTCs in 23 of the patients. Live CTCs isolated from patient blood samples were examined for PSA and AR expression to discern the origin of the CTCs. We tested 6 CTCs and found all expressed PSA while 5/6 were positive for AR expression demonstrating that these CTCs are prostate derived. We have recently attempted to isolate CTCs from patients with localized prostate cancer. Thus far, we have obtained no CTCs from 4 patients prior to or immediately after surgery for localized prostate cancer. Currently we are analyzing the clinical data from our patients with CRPC evaluate whether cell number correlates with clinic features of their disease and the effects of therapy on CTC number. We anticipate preparation and submission of a manuscript in this calendar year.
KEY RESEARCH ACCOMPLISHMENTS:
• We were able to isolate live circulating tumor cells from prostate cancer patients.
• We were able to establish the purity and specificity of CTC using prostate specific marker assay.
Specific Aim 3: Perform gene expression biomarker assays on individual CTCs isolated from patients.
In our initial application we proposed doing a multiplex qPCR analysis of CTC using prostate specific marker genes. This includes finding ways to use Fluidigm technology which can accommodate up to 384 genes for comparison of gene expression profiles. Since our proposal started, there has been tremendous progress in DNA sequencing both in terms of technology and cost. We have begun using NexGen single cell sequencing methodology developed at Illumina Inc. (Hayward, CA) to interrogate gene expression (single cell RNA-Seq).
MagSweeper isolation has minimal effects on single cell transcriptomes
To demonstrate that the MagSweeper isolation process does not affect the global transcriptional profile of isolated cells, we performed single cell mRNA-Seq and detailed bioinformatics analysis on 2 groups of LNCaP cells. First set contained 4 fresh LNCAP cells picked just prior to spiking into blood, and the second set contained 4 LNCaPs after MagSweeper isolation from spiked normal blood. Isolated cells were stored frozen for at least a month to simulate storage conditions. BioAnalyzer traces of amplified cDNA from a fresh and a MagSweeper isolated cell revealed similar molecular weight peaks of amplification products centered at approximately 1000 base pairs (bp) (Figure 2A ).
To study genes differentially expressed between fresh and MagSweeper isolated single cells, we first used the Bioconductor edgeR package. We identified only 1 gene as differentially expressed between MagSweeper-isolated and control LNCaP cells at a false discovery rate (FDR) cutoff of 0.05 and none at a cutoff of 0.01. We also explored several other methods for identifying differences between the fresh and MagSweeper isolated cells. First, to characterize the degree of cell-to-cell variability, we asked how many genes had a very high fragments per kilobase of exon per million fragments mapped (FPKM) (>10) in at least 1 sample and a very low FPKM (<0.1) in at least one sample. We considered three different groups of samples: (1) 4 fresh cells (2) 4 MagSwept cells and (3) 2 fresh and 2 MagSwept cells. The number of highly variable genes in four fresh cells (215), four MagSwept cells (268) and a combination of 2 fresh and 2 MagSwept cells (239) was similar in all groups and likely reflects cell to cell heterogeneity.
Next we looked for genes that were relatively consistent across all the samples of a given type. We reasoned differential expression between the two sets of samples might be more readily detectable in this set of genes. Using this set of genes, we calculated the correlation of the number of reads per gene between each pair of samples, and found that the within-group correlations were no stronger than the between group correlations. In our last comparison we calculated the correlation of the number of reads per gene between each pair of samples, and found that the within-group correlations were no stronger than the between group correlations -that is, the cells did not cluster based on isolation method ( Figure 2B ). Finally in a separate study, we ran an Illumina expression microarray on pools of 10,000 LNCaP cells pre-and postMagSweeper isolation. Again, there was high cross-correlation (R 2 = 0.985) between
MagSweeper isolated cells and controls indicating that MagSweeper produces minimal alterations in gene expression (data not shown).
mRNA Seq of single prostate cancer CTCs
We prepared amplified cDNA from 67 CTCs isolated from 13 prostate cancer patients. CTCs were isolated after MagSweeping based on immunofluorescent staining for cells that were (EpCAM+/CD45-/DAPI -). Unlike cultured LNCaP cells, we found that there was a wide range of sizes of amplified cDNAs in patient-derived CTCs, reflective of initial RNA quality. We characterized traces of amplification products into 3 groups: 1) those with peaks centered around 1000 bps (good quality), 2) traces with intermediate length amplification products (partially degraded), and 3) traces with predominantly low molecular weight amplification products (degraded) ( Figure 2C ). Looking across all 67 CTCs, 21% had good quality RNA, 37% were partially degraded, and 42% of the samples were degraded ( Figure 2D ). RNA quality tended to be somewhat patient specific -for example patient 2 yielded the highest number (8/12) of good quality RNA samples. Using RNA quality as a guide, we sequenced the libraries of 24 CTCs which included representatives of all three RNA quality classifications, and aligned sequences to the human genome (build hg19) ( Figure 2D , % alignment). Based on sequence alignment of greater than five percent, sequence data for 20 CTCs collected from 4 patients (P1, P2, P3 and P4) were used for in depth analysis ( Figure 2E ).
mRNA-Seq data quality
To assess the mRNA-Seq data quality, coverage was calculated across a set of 600 hand-picked genes for quality control check of mRNA-seq data. The sequencing data from the single LNCaP, PC-3, and T24 cells passed the quality control standards for >60% alignment and <65% median alignment CV typically applied to large RNA input mRNA-Seq data sets ( Figure 3A ). In contrast, CTCs displayed higher coverage median CVs and lower percentage of alignments than cultured cells. Typical coverage plots for cell lines, normal prostate tissues, and CTCs are shown in Figure  3B . The cell lines displayed smooth coverage across the length of the transcript, while the normal prostate samples had a slight 3' bias, typical for tissue samples ( Figure 3B ). The CTCs had a wide range of coverage bias, as shown. Since oligo-dT was used to prime cDNA synthesis, a 3-prime bias in the coverage data suggests mRNA degradation.
mRNA-Seq data content
We looked at expression levels of several prostate makers and a leukocyte marker to establish that the patient-derived cells were of prostatic origin: androgen receptor (AR), prostate-specific antigen (PSA, KLK3), TMPRSS2, and the leukocyte marker CD45 in all CTC samples. Figure 4 
CTC Pathway Analysis
To find genes and pathways that were differentially activated in CTCs we compared transcript profiles of CTCs to those from normal prostate tissue and focused on genes that were over expressed in the CTCs. We reasoned that the varying degrees of RNA degradation in the CTCs would lead to unreliable counting of under expressed genes in the CTCs, especially since the half-life of RNA varies from gene to gene. We used a manual thresholding method to identify genes that were over expressed in CTCs. Specifically, we selected genes that were at least 100-fold higher in at least 2 of the CTCs compared to normal prostate tissue and that contained at least 10 mapped reads in at least one sample. By selecting transcripts that are highly differentially expressed, we also compensate for the fact that a fraction of the prostate tissue samples are epithelial in origin, at the expense of a high false negative rate.
We identified 181 genes over-expressed in CTCs compared to normal prostate tissue. The list contains many interesting transcripts germane to prostate cancer biology. For instance, all 3 CTCs from patient 1 expressed high levels of SPINK1, a transcript and protein identified as elevated in TMPRSS2-ERG fusion negative prostate cancers and associated with aggressive prostate cancer . In addition, there were a significant number of cell cycle and mitosis associated transcripts in the highly expressed gene set including CCNA2, CCNAB1 and B2, CDC20, CDCA3, CDCA3, CDCA8, CDL1, CDKN3, CENPE, CENPI, CENPK, CD28 and ASPM. Notably 4 transcripts (TOP2A, TK1, TPX2 and KIAA0101) expressed at high levels in CTCs were found in a list of 31 transcripts associated with disease recurrence after radical prostatectomy we published recently Interestingly, excluding P2 from the analysis yields a weaker but still significant association with prostate cancer. This is consistent with the observation that the CTCs from P2 yielded significantly better quality libraries.
KEY RESEARCH ACCOMPLISHMENTS:
• We were able to test single cell whole trancriptome amplification and sequencing protocol on 20 CTCs isolated from 4 prostate cancer patients.
• Using this protocol we could reproducibly amplify 66% of mRNA pool from a single cell.
• The gene expression / sequencing profile obtained from the single CTC does demonstrate its origin from prostate.
• IPA analysis does suggest the link between the gene expression profile of CTC and prostate cancer development.
REPORTABLE OUTCOMES:
Our manuscript entitled "mRNA-Seq of Single Prostate Cancer Circulating Tumor Cells Reveals Recapitulation of Gene Expression and Pathways Found in Prostate Cancer" was published in PLoS-One in Nov 2012. This manuscript is highly accessed at the PLoS-ONE website, has been circulated in social media, and has already been cited 12 times per Google Scholar.
Overall:
We are very excited to report significant progress made on all 3 specific aims. We have optimized protocols for prostate specific CTC isolation and single cell whole transcriptome sequencing which has now been tested in cells isolated from number of metastatic prostate cancer patients. We believe that generating a dataset of CTC transcriptomes will provide significant insights into CTC biology and could have clinical utility. Our efforts are continuing in collecting CTCs from prostate cancer patients and banking these CTCs for characterization. We are looking into better and improved NexGen gene enrichment characterization methods.
Future Aims:
We have expanded our CTC research efforts in improving the sensitivity of both EpCAM+ and EpCAM-CTCs. There is a general agreement within the CTC community of presence of diversity in CTC population possibly undergoing transient epithelial to mesenchymal transition (EMT) and/or its converse -MET. Cells that undergo EMT can lose expression of epithelial surface markers such as EpCAM, making isolation impossible. Intriguing data in breast cancer suggests that EMT and MET transitions can be operative in acquisition of resistance to chemotherapy and biological therapies (Yu. et al. 2013 ). If that is the case, measurement of all types of CTCs could be important in assessing response to therapy and could serve as a guide to therapy. So a CTC capture strategy effective for all cell populations could provide a better measure for estimating the risk of the disease, possibility of recurrence and response to therapy. To that end, we are developing an antibody cocktail that could capture both epithelial and mesenchymal populations of cells. We plan to apply this capture method to early and late stage prostate cancer patients. In addition, preliminary data suggests our antibody cocktail might be broadly applied in other cancer types.
Moving forward, we plan to apply for additional funding to expand our studies of CTCs and are formulating several aims. Very likely these will include:
• To test whether our new antibody cocktail provides higher yields and sensitivity in isolating prostate cancer CTCs across a broader range of patients. 
Introduction
Circulating tumor cells (CTC) are cells that part from a primary tumor or metastasis and enter the blood stream via the leaky vasculature that arises around a growing tumor. Once in the blood, CTCs encounter damaging stresses associated with hemodynamic shear, low oxygen conditions, lack of anchorage sites, and immune system attack [1, 2] . A small number of CTCs survive however and extravasate into surrounding tissues to seed metastasis or reseed the primary tumor [3] . Described over a century ago [4] , CTCs can be now enumerated using the FDA approved CellSearch platform to provide prognostic information regarding survival for metastatic breast, colon and prostate cancer patients [5] [6] [7] . Moving beyond enumeration, several groups have suggested that genetic and transcriptional analysis of individual CTCs might be leveraged to make personalized medical decisions for cancer therapy and provide insights into the biological processes involved in metastasis [8] [9] [10] .
Several methods have been exploited to isolate CTCs from red and white blood cells (WBCs). Differentiating physical properties and surface markers of CTCs have been utilized for their isolation by filtration [11] , microfluidic chip [12, 13] , buoyant density centrifugation [14] , immunomagnetic selection [15, 16] , functional enrichment and detection [17, 18] , and automated immune microscopy [19, 20] . Immunomagnetic enrichment with antiEpCAM beads followed by fluorescence activated cell sorting has recently been shown to be an effective approach for isolating CTCs relatively free of hematopoietic cells [21] . Of the platforms currently in use for isolating CTCs, the MagSweeper technology provides great ease of use and access to highly pure, intact, individual CTCs suitable for genetic and proteomic analysis [22, 23] .
CTCs are generally present in low numbers in patient blood samples (typically 1 per 10 7 nucleated cells in blood) so extracting maximal information from single or available CTCs isolated from a patient's blood sample is essential. Next generation DNA sequencing is particularly well suited for deep interrogation of cancer genomes and transcriptomes [24] even when applied at the single cell level [25] . 
Materials and Methods

Ethics Statement
This study was reviewed and approved by Stanford's Human Subjects Research Compliance Board and adhered to HIPPA regulations. All human subjects signed informed consent prior to blood sample collection.
Patient samples and blood collection
Patient samples were collected in 10 ml EDTA tubes (Beckton Dickenson) and processed within 12 hours of collection. Samples were collected according to guidelines specified and approved by an Institutional Review Board and after informed consent. For comparisons between MagSweeper and CellSearch, a second 7.5 ml blood sample was collected in a CellSave tube. CellSearch assays were performed by Quest diagnostics. Total RNA from three histologically normal prostate tissues were obtained from surgically removed prostates under a separate IRB-approved protocol.
Cell Culture and Cell Spiking
LNCaP, PC-3, and T24 cells were purchased and cultured according to conditions specified by the American Type Culture Collection (ATCC). Following dissociation live and dead cells were determined by Trypan blue exclusion. For spiking, cells were diluted to approximately 3610 3 cells per ml and cell concentration verified by spotting and counting six, ten microliter aliquots of cells spotted on a glass microscope slide. No correction for dead cells based on Trypan blue exclusion was used prior to spiking cells.
Bead Binding and Cell Surface Staining
Custom 1.5 um Streptavidin coated magnetic beads were functionalized with a custom biotinylated monoclonal antibody directed against extracellular human EpCAM epitope. Two 3.75 ml volumes of blood per sample were subjected to red blood cell lysis with 10 volumes of 16 PharmLyse (BD Biosciences) for 15 minutes at room temperature. Remaining cells were pelleted at 4uC for 15 min at 3006 g. Cell pellets were transferred with 261 ml aliquots of 1%BSA/PBS/5 mM EDTA into a 2 ml flat bottom microcentrifuge tube (VWR International). Cells were then pelleted for 5 minutes at 5106 g. Cell pellets were resuspended in a total volume of 1 ml of 1%BSA/PBS/5 mM EDTA containing 15 ul of Alexa 488 anti-human CD45 (Life Technologies) and 30 ul of our custom anti-EpCAM beads.
Samples were rotated for 30 minutes at 4uC followed by addition of 20 ul of Phycoerythrin (PE) anti-human EpCAM monoclonal antibody (BD Biosciences 347198). Samples were then rotated at 4uC for an additional 30 minutes and then transferred to a well in a 6 well plate containing 6 ml of 1%BSA/PBS/5 mM EDTA. Samples were mixed once by pipetting up and down in a 10 ml pipette, and plates were spun for 5 minutes at 400 rpm, followed by incubation for 15 minutes at 4uC prior to MagSweeper isolation. In some spiking experiments, LNCaP cells were labeled prior to spiking with CFDA (Life Technologies) following manufacturer's instructions.
MagSweeper and Single Cell Isolation
Putative CTCs were isolated using two rounds of MagSweeper isolation. Cells isolated after the first round of MagSweeping were released and stained in a well of a 6-well plate containing 500 nM membrane impermeable DAPI (Life Technologies) so that membrane compromised cells could be identified. Following a second round of MagSweeping cells were dispersed and pelleted at 400 rpm for 1 min in a well of a 6-well low adhesion plate in 10% Superblock (ThermoFisher)/PBS. Wells were viewed with an Olympus inverted microscope equipped for epiflouresence. Putative CTCs were identified as cells that stained positive for PE anti-EpCAM and negative for Alexa 488 anti-CD45. Putative CTCs that were DAPI+ were excluded from further analysis. DAPI negative putative CTCs were isolated in 1 ul of 10% Superblock/PBS with a pipetteman into a 0.2 ml PCR tube containing 2.5 ul of 5% Ribonuclease Inhibitor (Life Technologies)/0.2% Triton X-100 (10% solution, Sigma) prepared in nuclease free water. Collected cells were flash frozen on dry ice and stored at 280uC. Cell purity was measured as the number of spiked cells recovered divided by the number of spiked cells recovered plus the number of leukocytes.
Single Cell mRNA-Seq
Single cells were lysed and RNA reverse transcribed using the SMARTer Ultra Low Input RNA for Illumina Sequencing kit (Clontech). cDNA was amplified using the Advantage 2 PCR kit (Clontech) for 18-25 cycles prior to conversion into a Illumina compatible DNA sequencing library using the Nextera DNA Sample Prep Kit (Illumina) and 12 cycles of PCR to amplify the library. Libraries were quantified using a BioAnalyzer (Agilent) and qPCR using a Kappa Syber Green PCR kit (Kappa Biosciences) on an IIlumina ECO qPCR machine. Paired end flow cells were prepared using 8 pM of Nextera library per lane on a cBot (Illumina) and sequenced using single 50 bp reads on an Illumina GAIIx .
Alignment
Sequencing data was collected with RTA version 1.9 and fastq files were generated with Casava 1.8. Reads that did not pass Illumina's standard quality filter were removed by default. Reads were aligned to hg19 with tophat v1.3.3 and counts per transcript were calculated for hg19 in iGenomes using cufflinks v1.1 with the options: -GTF ,genes.gtf. -max-bundle-frags 20000000. Geneby-gene raw counts and fragments per kilobase of exon per million fragments mapped (FPKM) were generated from the cufflinks isoform.fpkm_tracking file by identifying all the transcripts with the same gene name and taking, respectively, the sum of coverage multiplied by transcript length/read length for each transcript and the sum of the FPKM for each transcript. The raw counts and FPKMs were used in all the downstream analysis, except the QC step.
RNA-Seq Data Quality Control
Quality control (QC) was done using an internal Illumina RNASeq QC script. Base-by-base coverage was calculated across a hand-picked set of 600 quality control genes that are chosen from RefSeq and are highly mappable and highly abundant in universal human RNA (UHR) samples (Agilent) . Highly mappable means that .90% of bases for a selected transcript have 100% mappability. High expression in UHR means that only genes with average coverage .16 were selected. So for a given transcript 1000 bp in length there are at least 20 reads of 50 bp mapped to it. Genes in this set with greater than 1 FPKM were used to calculate additional statistics. The median coverage across all the length-normalized QC genes with greater than 1 FPKM was plotted. For each quality control gene with greater than 1 FPKM, the coefficient of variation was calculated across the gene, and the median of all the CVs was determined.
Unsupervised Clustering
Unsupervised hierarchical clustering [26] was done with the heatmap function in R, with the default Euclidean distance used as the dissimilarity metric. For each sample, the 100 genes with the highest FPKM were selected and the resulting pool of 312 genes was used in the clustering.
LNCaP expression analysis
EdgeR [27] was run using moderated tagwise dispersions with the raw counts per gene as input. Correlation between samples was calculated based on the raw number of reads mapped to each gene.
Genes over-expressed in CTCs
Due to the inherent variability in single cell data, coupled with the varying degrees of apparent mRNA decay observed in the CTCs, a simple thresholding method was used to identify overexpressed genes. For each gene the ratio of the 2 nd highest FPKM value among the set of CTCs to the FPKM in the normal prostate RNA was calculated. Genes with a ratio of at least 1006 and at least 10 total reads in one of the CTCs were selected. GO ontologies were generated using the Panther Classification System (http://www.pantherdb.org/) [28] . 
Results
MagSweeper metrics for CTC isolation
A new prototype of the Magsweeper [22] was developed that is compatible with operation in most biosafety cabinets ( Figure 1A) . To assess the performance of this platform, over an 11 month period, 100 LNCaP cells were repeatedly spiked into 3.75 ml of normal blood and isolated with the MagSweeper (n = 54 experiments and 11 blood donors). Prior to spiking, LNCaP cell viability measured by Trypan blue exclusion was 89%68%. During isolation from spiked blood LNCaP cells were fluorescently labeled with antibodies against EpCAM and CD45 to distinguish LNCaP cells from WBCs, and the membrane impermeable nuclear stain DAPI was used to identify dead (membrane compromised) cells. Post-isolation we recovered a mean of 81%616% of live spiked LNCaP cells (EpCAM+/CD452/ DAPI2) ( Figure 1B , blue line) while DAPI staining revealed an additional 12%66% of the isolated LNCaP cells that were membrane compromised (EpCAM+/CD452/DAPI+). Since the original cell spike contained 11% dead cells (measured by Trypan blue exclusion) recovery of 12% DAPI positive cells following MagSweeping indicates that damage to spiked LNCaP cells during the entire procedure is minimal. Normal, unspiked blood samples failed to yield EpCAM positive cells (data not shown).
To assess purity of ultra-rare cells after MagSweeping, 7.5 ml of normal donor blood was spiked with 10 CFDA labeled cells (n = 6 experiments and 4 donors) and processed according to our protocol for CTC isolation. Captured LNCaP cells were identified by fluorescent detection of CFDA, while contaminating WBCs were identified by positive CD45 staining. Following magnetic sorting a mean percentage LNCaP recovery of 63%625% was observed. Enumeration of CD45 positive cells yielded an initial purity of isolated LNCaP cells after MagSweeper cell isolation of 10%66% and 100% post single-cell isolation using a pick and place method (Fig. 1C) .
We next performed a comparative analysis of MagSweeper versus CellSearch in enumeration of CTC in blood samples from patients with metastatic prostate cancer. At the time of draw, two 7.5 ml samples of blood were collected, one sample in a standard EDTA tube for MagSweeper cell isolation and a second in a CellSave tube for analysis by an independent lab (Quest Diagnostics) using the CellSearch assay. Immunofluorescent staining of MagSweeper isolated cells identified CTCs as EpCAM positive and CD45 negative. CTCs were easily distinguished from WBC which were CD45 positive, EpCAM negative (Fig. 1D) . Numbers of completely purified CTCs enumerated by MagSweeper isolation and CellSearch were compared and found to be reasonably similar, with a mild trend observed toward better CTC capture using the MagSweeper in samples with low CTC numbers ( Figure 1E ).
MagSweeper isolation has minimal effects on single cell transcriptomes
To assess whether the MagSweeper isolation process affected the global transcriptional profile of isolated cells, we performed single cell mRNA-Seq on 4 fresh LNCaP cells just prior to spiking into blood, and on 4 LNCaPs after MagSweeper isolation from spiked normal blood. Isolated cells were stored frozen for at least a month to simulate storage conditions. BioAnalyzer traces of amplified cDNA from a fresh and a MagSweeper isolated cell revealed similar molecular weight peaks of amplification products centered at approximately 1000 base pairs ( Fig. 2A) .
To study genes differentially expressed between fresh and MagSweeper isolated single cells, we first used the Bioconductor edgeR package. We identified only 1 gene as differentially expressed between MagSweeper-isolated and control LNCaP cells at a false discovery rate (FDR) cutoff of 0.05 and none at a cutoff of 0.01.
We also explored several other methods for identifying differences between the fresh and MagSweeper isolated cells. First, to characterize the degree of cell-to-cell variability, we asked how many genes had a very high FPKM (.10) in at least 1 sample and a very low FPKM (,0.1) in at least one sample. We considered three different groups of samples: (1) 4 fresh cells (2) 4 MagSwept cells and (3) 2 fresh and 2 MagSwept cells. The number of highly variable genes in four fresh cells (215), four MagSwept cells (268) and a combination of 2 fresh and 2 MagSwept cells (239) was similar in all groups and likely reflects cell to cell heterogeneity. In another comparison we calculated the correlation of the number of reads per gene between each pair of samples, and found that the within-group correlations were no stronger than the between group correlations -that is, the cells did not cluster based on isolation method ( Figure 2B ). Finally in a separate study, we ran an Illumina expression microarray on pools of 10,000 LNCaP cells pre-and post-MagSweeper isolation. Again, there was high cross-correlation (R 2 = 0.985) between MagSweeper isolated cells and controls indicating that MagSweeper produces minimal alterations in gene expression (data not shown).
mRNA-Seq of single prostate cancer CTCs
We prepared amplified cDNA from 67 CTCs isolated from 13 prostate cancer patients. CTCs were isolated after MagSweeping based on immunofluorescent staining for cells that were (EpCAM+/CD452/DAPI2). Unlike cultured LNCaP cells (Figure 2A ), we found that there was a wide range of sizes of amplified cDNAs in patient-derived CTCs, reflective of initial RNA quality. We characterized traces of amplification products into 3 groups: 1) those with peaks centered around 1000 bps (good quality), 2) traces with intermediate length amplification products (partially degraded), and 3) traces with predominantly low molecular weight amplification products (degraded) (Fig. 2C) . Looking across all 67 CTCs, 21% had good quality RNA, 37% were partially degraded, and 42% of the samples were degraded (Fig. 2D ). RNA quality tended to be somewhat patient specific -for example patient 2 yielded the highest number (8/12) of good quality RNA samples. Using RNA quality as a guide, we sequenced the libraries of 24 CTCs which included representatives of all three RNA quality classifications, and aligned sequences to the human genome (build hg19). Based on sequence alignment score of greater than five percent, sequence data for 20 CTCs collected from 4 patients (P1, P2, P3 and P4) were selected for further in depth study (Fig. 2E) .
mRNA-Seq data quality
To assess the mRNA-Seq data quality, coverage was calculated using a quality control script and a handpicked set of 600 quality control genes that are highly mappable and expressed in universal human RNA (see Methods, RNA-Seq Data Quality Control for definition). The sequencing data from the single LNCaP, PC-3, and T24 cells passed the quality control standards for .60% alignment and ,65% median alignment CV typically applied to large RNA input mRNA-Seq data sets (Fig. 3A) . In contrast, CTCs displayed higher coverage median CVs and lower percentage of alignments than cultured cells. Typical coverage plots for cell lines, normal prostate tissues, and CTCs are shown in Figure 3B . The cell lines displayed smooth coverage across the length of the transcript, while the normal prostate samples had a slight 39 bias, typical for tissue samples (Fig. 3B) . The CTCs had a mRNA-Seq of Human Circulating Tumor Cells PLOS ONE | www.plosone.orgwide range of coverage bias, as shown. Since oligo-dT was used to prime cDNA synthesis, a 3-prime bias in the coverage data suggests mRNA degradation.
mRNA-Seq data content
To understand transcript abundance, variation and range in CTCs, we compared the distributions of FPKM values of all RefSeq RNAs detected in CTCs and LNCaP cells (Tables S1 and  S2 ). Measurements of RefSeq transcripts with $10 FPKM revealed in LNCaP cells (n = 4) 46226136.2 transcripts (with a range of 4485 to 4786 transcripts). In contrast, in CTCs (n = 20) the number of RefSeq transcripts with $10 FPKM was 23626865 transcripts (with a range of 1233 to 3987 transcripts).
Next, we looked at expression levels of several prostate makers and a leukocyte marker to establish that the patient-derived cells were of prostatic origin: androgen receptor (AR), prostate-specific antigen (PSA, KLK3), TMPRSS2, and the leukocyte marker CD45 in all CTC samples. Figure 4A shows the FPKM of each of these markers in patient CTCs, tissue culture cell lines and normal prostate, with values of .1 FPKM shaded in green. All but one of the CTCs was positive for at least one of the prostate markers. LNCaP and normal prostate showed expected expression of these prostate markers. PC-3 lacked KLK3 and AR expressed, as expected [29] but did express TMPRSS2. Importantly, all the CTCs and the cell lines were negative for the WBC marker CD45. Normal prostate, which is comprised of many cell types including WBCs, was positive for CD45 expression as was the single WBC that was subjected to mRNA-Seq. Finally, T24, a bladder cancer cell line did not express any of these markers. To understand how patient CTCs relate to one another, we performed an unsupervised clustering analysis of all patient CTCs. The analysis revealed that with the exception of two CTCs (P2.9 and P1.2), all CTCs from individual patients clustered in a patient specific manner (Fig. 4B) .
CTC Pathway Analysis
To find genes and pathways that were differentially activated in CTCs we compared transcript profiles of CTCs to those from normal prostate tissue and focused on genes that were over expressed in the CTCs. To normalize the RNA-Seq data based on gene sizes and number of mapped fragments, we used tophat and cufflinks to determine FPKM. We reasoned that the varying degrees of RNA degradation in the CTCs would lead to falsepositive counting of under expressed genes in the CTCs, especially since the half-life of RNA varies from gene to gene. We used a manual thresholding method to identify genes that were overexpressed in CTCs. Specifically, we selected genes that were at least 100-fold higher in at least 2 of the CTCs compared to normal prostate tissue and that contained at least 10 mapped reads in at least one sample.
We identified 181 genes over-expressed in CTCs compared to normal prostate tissue (Table S3) . To gain an overview of the range of biological functions associated with these transcripts, Gene Ontology annotations we derived from the GoSlim database using the Panther Classification System browser [28] (Fig. 4C) and categorized for biological processes. Out of 181 genes, 110 yielded 173 process hits which were classified into 14 biological processes. These were displayed using the Panther Pie Cart feature (Fig. 4C) . Among the remaining 71 gene annotations not classified by GoSlim, 37 were non-coding RNAs including members of the MIR, SCARNA, SNAR, SNORA,SNORD and VTRNA families. The remaining 34 transcripts could be identified using GeneCards. Examination of the transcripts classified by biological processes revealed that one third were associated with either metabolic processes (23%, GO:0008152) or the cell cycle (10%, GO:0007049), consistent with mitotically active cells (Fig. 4C) . Cell cycle and mitosis associated transcripts in the highly expressed gene set including TPX2, CCNA2, CCNB1 and B2, CDC20, CSK2, CDC2, CDKN3, CENPE, CD28 ,TOP2A, ORC1L, NUF2, CDK1, KIF2C, PTTG1 and TTK.
Interestingly, the list contains many transcripts germane to prostate cancer biology. For instance, all 3 CTCs from patient 1 expressed high levels of SPINK1, a transcript and protein identified as elevated in TMPRSS2-ERG fusion negative prostate cancers and associated with aggressive prostate cancer [30] . CTCs from patients 1 and 2 expressed high levels of BIRC5 (Survivin), an anti-apoptotic gene expressed at high levels in castrationresistant prostate cancer. CTCs also expressed cancer associated transcripts (BAGE, BAGE3, CT45A1, CT45A4, CT45A5, CT45A6, CTAG18, CTAG2, MAGEA12, MAGEA1, MAGEA3, • developmental process (60:0032502)
• immune syst em process (60:0002376)
• reprod uction (60:0000003)
• system process (60:0003008) 2% 1%
• cell adhesion (60:0007155)
cell cycl e (60 :0007049) cellular process (60:0009987)
• generation of precursor metabolites and energy (60:0006091)
• metabolic process (6 0:0008152)
• response to stimulus (60:0050896)
• transport (60:0006810) 4%2% MAGEA6, MAGEC1, MAGEC2, and PTTG1) and transcripts important in regulating development (HOXB7, HOXB8, HOXB9, NANOGNB, and LOC404266). Notably 4 transcripts (TOP2A, TK1, TPX2 and KIAA0101) expressed at high levels in CTCs were found in a list of 31 transcripts associated with disease recurrence after radical prostatectomy we published recently [31] . Using Ingenuity Pathway Analysis (IPA), we looked for overrepresented pathways and gene sets. The top Diseases and Disorders was Cancer and the top Canonical Pathway was ''Cell Cycle: G2/M DNA Damage Checkpoint Regulation. Looking specifically at genes overlapping the IPA function Prostate Cancer, 9 genes were identified: AR, TK1, PLK1, MAGEA1, MAGEC1, MAGEC2, CTAGB1, BIRC5, and TOP2A. The CTCs from patient 2 contributed most significantly to these results. Repeating these analyses with only genes identified in P2 verses normal prostate tissue produced very similar results with highly significant p-values. Interestingly, excluding P2 from the analysis yields a weaker but still significant association with prostate cancer. This is consistent with the observation that the CTCs from P2 yielded significantly better quality libraries.
Discussion
We have produced a new generation of MagSweeper which employs more sophisticated cell capture hardware and software than a previous version [22] , and has a reduced footprint compatible with operation in most biosafety cabinets. These improvements combined with a multi-marker staining protocol allow the user to distinguish CTCs by fluorescent staining of cell surface markers. Validation of MagSweeper performance revealed that the mean capture of live LNCaP cells spiked into blood is 81%616% which is comparable with the capture reported for high EpCAM expressing epithelial cancer cell lines spiked into blood on other CTC capture platforms [32] . In a comparative enumeration study with the CellSearch platform using prostate patient samples, MagSweeper allowed enumeration of comparable numbers of CTCs with a slightly better recovery of CTCs from patient samples with low starting numbers of CTCs (Fig. 1E) . However, unlike other CTC isolation technologies (CellSearch cartridges, and CTC and OncoCEE chips) MagSweeper technology allows isolation and characterization of single CTCs, rather than pooled CTCs that are contaminated with variable numbers of WBCs (Fig. 1C, Cell Isolation, Fig. 4A ). Furthermore, inclusion of DAPI as a dead cell exclusion marker allows discrimination of intact CTCs from damaged CTCs and CTC fragments that have been observed by several groups using the CellSearch [33] , and other automated microscopy platforms [19, 34] . Although we have used EpCAM based capture and cell surface staining to isolate and identify single prostate cancer CTCs, combinations of capture and staining antibodies can be easily reconfigured for use with the MagSweeper to isolate CTCs from other malignancies or to isolate other cell types. Finally, single cell isolation using the MagSweeper does not appreciably alter gene expression. While single cells pre and post-MagSweeper isolation showed expected heterogeneity in transcriptome expression patterns from cell to cell, we were unable to find patterns of gene expression that were correlated with MagSweeper processing. This finding suggests that cell autonomous as opposed to extrinsic factors such as MagSweeper isolation govern gene expression at the level of the single cell (Fig. 2B) .
The MagSweeper isolation protocol appears to be a relatively gentle method for isolating CTCs, with a mean cell attrition rate for spiked LNCaP of 1%. Furthermore, dead and membrane compromised cells are stained using DAPI allowing identification and isolation of live, membrane intact cells, and those cells most likely to yield intact DNA and RNA. With this protocol single LNCaP, PC-3 and T24 cells showed high quality RNA after amplification as judged by size of amplified cDNA ( Fig. 2A) and passing mRNA-Seq quality control metrics for alignment, median alignment CV and positional coverage in a handpicked panel of 600 quality control genes ( Fig. 3A and 3B) . Therefore, we suspect that the heterogeneity in RNA quality present in CTCs isolated from patient samples (Fig. 2C, 3A and 3B ) is due to features of CTC biology in vivo and not due to technical features of MagSweeper CTC isolation. Patients with the highest numbers of CTCs tended to yield CTCs with better RNA quality. Since all patients in this study were on therapy (Table S4) , differences in RNA quality are likely related to treatment effects or host factors that affect CTC viability and apoptosis. Degradation of mRNA is an early event in apoptosis, possibly upstream of caspase activation [35] , and therefore might occur in dying cells that are physically intact as judged by lack of DAPI staining. Accumulating evidence suggests that apoptotic CTCs are routinely isolated from cancer patient blood samples. Using the CellSeach platform, FISH, and flow cytometry in conjunction with the M30 antibody which recognizes caspase cleaved CK18, several groups have shown that a significant number of CTCs isolated from metastatic prostate cancer patients are apoptotic [34, [36] [37] [38] . Detection of apoptotic CTCs is not platform or cancer type specific. Using fiber optic array scanning technology and automated fluorescence imaging, many CTCs isolated from metastatic breast cancer patients are apoptotic morphologically and stain positively in fluorescent TUNEL assays [19, 33] .
Despite heterogeneity of CTC RNA quality, we were able to perform single cell transcriptome analysis and confirm that the CTCs were prostatic in origin. Expression of the androgen receptor and target downstream genes such as KLK3 and TMPRSS2 in all but one of the CTCs identifies them as being of prostate origin (Fig. 4A) . Furthermore, none of the CTCs, or single LNCAP, PC-3 and T24 cell lines sequenced expressed CD45, a marker for WBCs. Larger studies of isolated CTCs will be necessary to understand the degree of cell-to-cell heterogeneity in gene expression as well as the effects of RNA quality on the fidelity of transcript levels measured by whole transcriptome sequencing in single cells.
Pathway analysis confirmed activation of androgen receptor (AR) signaling pathways, which are known to be central to prostate cancer biology. In addition many genes associated with cell cycle regulation and mitotic spindle are up regulated in the CTCs. While high levels of expression of these transcripts might be expected in malignant cells, it is notable that CTCs showing high levels of expression of spindle-associated transcripts were derived from patients on taxane chemotherapy. Taxanes target the mitotic spindle so it is possible that these transcripts were up-regulated in response to chemotherapy and that this up-regulation could mediate response or resistance to taxane chemotherapy. Several of the transcripts identified in the CTCs have been correlated with aggressive behavior in localized prostate cancer (e.g. PLK-1, TOP2A) so it is interesting to observe these markers in cells from patients with highly advanced prostate cancers [39, 40] . MAGE A1 and CTAG1B show a complex pattern of expression in samples of prostate carcinomas [41] . MAGE C2 is expressed in a small percentage of primary prostate cancers with more frequent expression found in metastatic and castration resistant cancer [42] . Finally, it might be possible to use CTCs to identify therapeutic targets for advanced prostate cancer. For example, CTCs from 2 patients expressed high levels of BIRC5 transcripts. BIRC5 encodes the bi-functional protein survivin which has both anti-apoptotic and mitotic functions in a cell [43] . Survivin has been implicated in castrate resistant prostate cancer and therapeutic antisense RNA to survivin shows effectiveness in treating castrate resistant prostate cancer [44] . In patient 1, SPINK1 was identified in all 3 CTCs analyzed, and accumulating evidence suggests this defines a subtype of prostate cancer that is susceptible to therapies targeting SPINK1 or EGFR (cetuximab) [30] .
Previous molecular characterizations of CTCs target a single or a few disease-associated biomarkers. For example, pooled CTCs have been assayed for HER2 in breast cancer using FISH [32] , TMPRRSS2-ERG rearrangements in prostate cancer using RT-PCR [8] and EGFR mutations in non-small cell lung cancer [45] . Microarray-based assessments of gene expression have been carried out on pools of prostate, breast and colon cancer CTCs [46] and whole genome amplification coupled with array comparative genomic hybridization has been used to look at copy number variation in small pools of prostate CTCs [21] . With the exception of FISH, no previous technology has allowed assessment of gene expression of single CTCs, and pooling of samples could obscure cell-to-cell variations in expression that are biologically interesting and important. Our demonstration that mRNA-Seq can be carried out on single CTCs, and development of a platform that allows isolation of highly pure individual CTCs offers an opportunity to advance understanding of gene expression in individual CTCs and test whether CTC genomic information can be used in clinical decision making. 
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